What's in Norgine's pipeline?

Norgine has 23 drugs in our index: 6 marketed, 0 filed, 8 in Phase 3, 3 in Phase 2, 6 in Phase 1.

Which companies overlap with Norgine's portfolio?

Top competitors by shared drug class: Ahmed M Maged, MD, Amsterdam UMC, location VUmc, Azienda Policlinico Umberto I, Bayer, Benaroya Research Institute.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/norgine.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Norgine — Portfolio Competitive Intelligence Brief

Norgine pipeline: 6 marketed, 0 filed, 8 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

6 marketed 0 filed 8 Phase 3 3 Phase 2 6 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Fleet	Fleet	marketed			Other
COLOPEG	COLOPEG	marketed
NER1006	NER1006	marketed			Other
CitraFleet	CitraFleet	marketed	Osmotic laxative bowel preparation		Gastroenterology
Moviprep	Moviprep	marketed			Other
MOVICOL	MOVICOL	marketed			Metabolic
NER1006, Day Before-Only Dosing	NER1006, Day Before-Only Dosing	phase 3	Osmotic laxative / Bowel cleansing agent		Gastroenterology
Trisulfate solution	Trisulfate solution	phase 3
PEG 3350 plus electrolytes	PEG 3350 plus electrolytes	phase 3	Osmotic laxative		Gastroenterology
NRL972	NRL972	phase 3	Neutrophil elastase inhibitor	Neutrophil elastase (NE)	Respiratory / Pulmonology
SP+MS, Day Before-Only Dosing	SP+MS, Day Before-Only Dosing	phase 3	Bowel preparation agent / Laxative combination		Gastroenterology
MOVIPREP, 2-Day Split-Dosing	MOVIPREP, 2-Day Split-Dosing	phase 3	Osmotic laxative bowel preparation	Osmotic agent (polyethylene glycol 3350)	Gastroenterology

Therapeutic area mix

Gastroenterology · 7
Other · 3
Metabolic · 1
Respiratory / Pulmonology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Ahmed M Maged, MD · 1 shared drug class
Amsterdam UMC, location VUmc · 1 shared drug class
Azienda Policlinico Umberto I · 1 shared drug class
Bayer · 1 shared drug class
Benaroya Research Institute · 1 shared drug class
Bo-In Lee · 1 shared drug class
Braintree Laboratories · 1 shared drug class
Aboca Spa Societa' Agricola · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Norgine:

Cite this brief

Drug Landscape (2026). Norgine — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/norgine. Accessed 2026-05-13.